The company eliminates the logistical problems of using advanced 3D cell models for HTS. Scientists can take their 384-well plates out of the freezer, thaw them, and start testing on individual spheroids in 24 hours. No culturing, no tedious handling, no new equipment needed. Lucero enable drug developers to use complex in vitro models earlier in their assay cascades to make quicker and more accurate go/no-go decisions.
Lucero’s mission is to reduce preclinical H2L times by 20%.
Lucero
Lucero is developing the world’s first thaw-and-dose spheroid plates tailor-made for preclinical hit-to-lead (H2L) DMTA testing cycles.
